First Fiduciary Investment Counsel Inc. Sells 10,323 Shares of Pfizer Inc. (NYSE:PFE)

First Fiduciary Investment Counsel Inc. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 3.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 255,497 shares of the biopharmaceutical company’s stock after selling 10,323 shares during the quarter. First Fiduciary Investment Counsel Inc.’s holdings in Pfizer were worth $7,356,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of PFE. Briaud Financial Planning Inc bought a new position in Pfizer in the third quarter valued at approximately $30,000. GoalVest Advisory LLC grew its stake in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer in the third quarter valued at approximately $34,000. VisionPoint Advisory Group LLC lifted its position in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $36,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PFE shares. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Trading Up 0.5 %

Shares of PFE opened at $25.38 on Friday. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37. The business’s fifty day moving average is $26.96 and its 200-day moving average is $28.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a market cap of $143.72 billion, a price-to-earnings ratio of 70.50, a PEG ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the company posted $1.14 EPS. The company’s revenue for the quarter was down 41.3% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.62%. Pfizer’s payout ratio is 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.